Welcome to our dedicated page for Rain Enhancement news (Ticker: RAIN), a resource for investors and traders seeking the latest updates and insights on Rain Enhancement stock.
Rain Enhancement Technologies Holdco, Inc. develops, manufactures, and commercializes ionization precipitation generation technology for rainfall and snowpack enhancement. Its updates center on the Weather Enhancement Technology Array (WETA), U.S. installations, weather-modification permits, independent analyses of agricultural water benefits, and reported precipitation results in mountain and arid environments.
The company also reports research into adjacent atmospheric applications, including fog mitigation and air pollution or smog mitigation. Governance updates and commercialization milestones appear alongside technical disclosures about its chemical-free, solar-powered ionization approach.
Rain Therapeutics Inc. completed its IPO in April 2021, generating net proceeds of $121.9 million. The company plans to initiate a Phase 3 trial for RAIN-32 in well-differentiated/de-differentiated liposarcoma and an open-label Phase 2 basket trial for MDM2-amplified tumors, both set for 2H 2021. The first quarter results showed a net loss of $6.8 million compared to $2.6 million in Q1 2020, with R&D expenses significantly rising. Rain aims to end 2021 with a projected cash balance of $137 million to $147 million.
Rain Therapeutics has appointed co-founder Dr. Robert Doebele as president and chief scientific officer, enhancing its leadership as it approaches a critical Phase 3 clinical trial for RAIN-32. Dr. Doebele, an expert in precision oncology, will shape the company's strategy and operations. The leadership transition comes as Rain prepares for its Phase 3 trial for liposarcoma patients in late 2021. The company focuses on precision therapies that target oncogenic drivers, notably RAIN-32, an oral MDM2 inhibitor. Rain is positioned for growth following a recent IPO.
Rain Therapeutics Inc. has announced the pricing of its initial public offering (IPO) of 7,352,941 shares at $17.00 per share, aiming for gross proceeds of approximately $125.0 million. The shares are set to trade on the Nasdaq under the ticker symbol RAIN starting April 23, 2021. A 30-day option for underwriters to purchase an additional 1,102,941 shares at the IPO price is also provided. The offering is expected to close on April 27, 2021, subject to standard closing conditions.